Evidence map›Paper›PMID 32643841›Full record

SynthesisHuman brain mapping2022

How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross-disorder meta-analytic comparison using the ENIGMA consortium findings.

Xavier Navarri, Mohammad H Afzali, Jacob Lavoie, Rajita Sinha, Dan J Stein, Reza Momenan, Dick J Veltman, Ozlem Korucuoglu, Zsuzsika Sjoerds, Ruth J van Holst and 11 more

Open access · goldAbstract readComparative StudyMeta-AnalysisMulticenter Study
In one paragraph

Synthesis in Human brain mapping, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 4 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 4 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Independent brain cortical signatures of risk for adolescent cannabis use and consequences of such use are moderated by sex.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Large-Scale Neuroimaging of Mental Illness.Current topics in behavioral neurosciences · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 13 institutions in 5 countries.

Xavier NavarriDepartment of Psychiatry, Université de Montreal, CHU Ste Justine Hospital, CHU Ste-Justine, Montreal, Canada.ORCID 0000-0003-4972-319X
Mohammad H AfzaliDepartment of Psychiatry, Université de Montreal, CHU Ste Justine Hospital, CHU Ste-Justine, Montreal, Canada.
Jacob LavoieDepartment of Psychiatry, Université de Montreal, CHU Ste Justine Hospital, CHU Ste-Justine, Montreal, Canada.
Rajita SinhaDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.
Dan J SteinSAMRC Unit on Risk & Resilience in Mental Disorders, Department of Psychiatry and Neuroscience Institute, University of Cape Town, Cape Town, South Africa.
Reza MomenanNational Institute of Alcohol Abuse and Alcoholism (NIAAA), Bethesda, Maryland, USA.
Dick J VeltmanDepartment of Psychiatry, Amsterdam UMC location VUMC, Amsterdam, The Netherlands.
Ozlem KorucuogluAddiction, Development and Psychopathology (ADAPT) Lab, Department of Psychology, University of Amsterdam, Amsterdam, The Netherlands.
Zsuzsika SjoerdsCognitive Psychology Unit & Leiden Institute for Brain & Cognition, Institute of Psychology, Leiden University, Leiden, The Netherlands.
Ruth J van HolstAmsterdam Institute for Addiction Research, Department of Psychiatry, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.
Rob HesterMelbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia.
Catherine OrrDepartment of Psychiatry, University of Vermont, Burlington, Vermont, USA.
Janna CousijnDepartment of Psychology, University of Amsterdam, Amsterdam, The Netherlands.
Murat YucelMonash Institute of Cognitive and Clinical Neurosciences, and School of Psychological Sciences, Monash University, Monash, Australia.
Valentina LorenzettiBrain and Mental Health Research Hub, Monash Institute of Cognitive and Clinical Neurosciences, School of Psychological Sciences, Monash University, Melbourne, Australia.
Reinout WiersBrain Research Institute, University of California, Los Angeles, California, USA.
Neda JahanshadImaging Genetics Center, Mark & Mary Stevens Institute for Neuroimaging and Infomatics, Keck School of Medicine, University of Southern California, Marina del Rey, California, USA.
David C GlahnDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0002-4749-6977
Paul M ThompsonImaging Genetics Center, Mark & Mary Stevens Institute for Neuroimaging and Infomatics, Keck School of Medicine, University of Southern California, Marina del Rey, California, USA.
Scott MackeyDepartment of Psychiatry, University of Vermont, Burlington, Vermont, USA.
Patricia J ConrodDepartment of Psychiatry, Université de Montreal, CHU Ste Justine Hospital, CHU Ste-Justine, Montreal, Canada.
Centre Hospitalier Universitaire Sainte-Justine · CAAmsterdam Institute for Addiction Research · NLMonash University · AUUniversity of Southern California · USUniversity of Vermont · USYale University · USAllen Institute for Brain Science · USAmsterdam Neuroscience · NLLeiden University · NLNational Institute on Alcohol Abuse and Alcoholism · USSouth African Medical Research Council · ZAThe University of Melbourne · AUUniversity of Amsterdam · NL

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Training U54EB020403 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI THOMPSON, PAUL M · 2014 to 2018
$10.1M
ENIGMA- Addiction: Pooling of Existing Datasets to Identify Brain and Genetic Correlates of Addiction, Next StepsR01DA047119 · NIDA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HUGH P. GARAVAN · 2018 to 2026
$5.4M
Protocols, Statistics, Collaborative Method Development and ToolsPL1DA024859 · NIDA · YALE UNIVERSITY · PI SINHA, RAJITA · 2007 to 2011
$3.6M
ENIGMA-SD: Understanding Sex Differences in Global Mental Health through ENIGMAR01MH116147 · NIMH · UNIVERSITY OF SOUTHERN CALIFORNIA · PI THOMPSON, PAUL M · 2018 to 2021
$2.5M
Interdisciplinary Research on Stress, Self-Control & AddictionUL1RR024925 · NCRR · YALE UNIVERSITY · PI SINHA, RAJITA · 2007 to 2007
$849k
ENIGMA-Addiction: A Data-Pooling of Brain and Genetic Correlates of AddictionR21DA038381 · NIDA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI GARAVAN, HUGH P. · 2014 to 2015
$442k
NCATS NIH HHS UL1 TR001863NCRR NIH HHS UL1 RR024925NIBIB NIH HHS U54 EB020403NIDA NIH HHS 1R01DA047119-01NIDA NIH HHS 1R21DA038381NIDA NIH HHS PL1 DA024859NIDA NIH HHS PL30-1DA024859-01NIDA NIH HHS R01 DA047119NIDA NIH HHS R21 DA038381NIH HHS U54 EB 020403NIH HHS UL1-RR24925-01NIMH NIH HHS R01 MH116147
6 · The paper itself

Abstract

Alcohol use disorder (AUD) and cannabis use disorder (CUD) are associated with brain alterations particularly involving fronto-cerebellar and meso-cortico-limbic circuitry. However, such abnormalities have additionally been reported in other psychiatric conditions, and until recently there has been few large-scale investigations to compare such findings. The current study uses the Enhancing Neuroimaging Genetics through Meta-Analysis (ENIGMA) consortium method of standardising structural brain measures to quantify case-control differences and to compare brain-correlates of substance use disorders with those published in relation to other psychiatric disorders. Using the ENIGMA protocols, we report effect sizes derived from a meta-analysis of alcohol (seven studies, N = 798, 54% are cases) and cannabis (seven studies, N = 447, 45% are cases) dependent cases and age- and sex-matched controls. We conduct linear analyses using harmonised methods to process and parcellate brain data identical to those reported in the literature for ENIGMA case-control studies of major depression disorder (MDD), schizophrenia (SCZ) and bipolar disorder so that effect sizes are optimally comparable across disorders. R elationships between substance use disorder diagnosis and subcortical grey matter volumes and cortical thickness were assessed with intracranial volume, age and sex as co-variates . After correcting for multiple comparisons, AUD case-control meta-analysis of subcortical regions indicated significant differences in the thalamus, hippocampus, amygdala and accumbens, with effect sizes (0.23) generally equivalent to, or larger than |0.23| those previously reported for other psychiatric disorders (except for the pallidum and putamen). On measures of cortical thickness, AUD was associated with significant differences bilaterally in the fusiform gyrus, inferior temporal gyrus, temporal pole, superior frontal gyrus, and rostral and caudal anterior cingulate gyri. Meta-analysis of CUD case-control studies indicated reliable reductions in amygdala, accumbens and hippocampus volumes, with the former effect size comparable to, and the latter effect size around half of that reported for alcohol and SCZ. CUD was associated with lower cortical thickness in the frontal regions, particularly the medial orbitofrontal region, but this effect was not significant after correcting for multiple testing. This study allowed for an unbiased cross-disorder comparison of brain correlates of substance use disorders and showed alcohol-related brain anomalies equivalent in effect size to that found in SCZ in several subcortical and cortical regions and significantly greater alterations than those found in MDD in several subcortical and cortical regions. Although modest, CUD results overlapped with findings reported for AUD and other psychiatric conditions, but appear to be most robustly related to reduce thickness of the medial orbitofrontal cortex.

Indexed as

Magnetic Resonance ImagingNeuroimagingBipolar DisorderBrainHumansMajor Depressive DisorderSchizophreniaSubstance-Related Disordersaddictionalcoholcannabisstructural neuroimaging

Identifiers

PMID32643841
PMCPMC8675406
OpenAlexW3041094200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.